Patents by Inventor Myrna A. Monck

Myrna A. Monck has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INTERLEUKIN 5 BINDING PROTEIN DOSAGE REGIMEN FOR USE IN TREATING POLYANGIITIS, HYPEREOSINOPHILIC SYNDROME, CHRONIC RHINOSINUSITIS WITH NASAL POLYPS (CRSWNP), OR CHRONIC RHINOSINUSITIS WITHOUT NASAL POLYPS (CRSSNP)
    Publication number: 20250042985
    Abstract: The present disclosure relates to pharmaceutical compositions comprising from about 100 mg to about 300 mg of an antigen binding protein which binds to IL-5. Compositions and antigen binding proteins of the disclosure are useful in the treatment of IL-5 mediated diseases, such as EGPA, HES, CRSsNP and CRSwNP, and can be administered about once every 6 months.
    Type: Application
    Filed: December 1, 2022
    Publication date: February 6, 2025
    Applicant: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Daren J. AUSTIN, Alienor C. BERGES, Nicholas P. BIRD, Myrna A. MONCK, Isabelle J. POULIQUEN, Melissa A. SHUMAN, Chiara ZECCHIN
  • Biopharmaceutical compositions
    Patent number: 12187791
    Abstract: The present disclosure relates to compositions for treating interleukin 5 (IL-5) mediated diseases, and related methods.
    Type: Grant
    Filed: April 30, 2024
    Date of Patent: January 7, 2025
    Assignee: GlaxoSmithKline Intellectual Property (No.2) Limited
    Inventors: Myrna A. Monck, Narendra B. Bam, Jennifer Dally, Michelle Spatara
  • Biopharmaceutical compositions
    Patent number: 12187790
    Abstract: The present disclosure relates to compositions for treating interleukin 5 (IL-5) mediated diseases, and related methods.
    Type: Grant
    Filed: April 30, 2024
    Date of Patent: January 7, 2025
    Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Myrna A. Monck, Narendra B. Bam, Jennifer Dally, Michelle Spatara
  • Biopharmaceutical compositions
    Patent number: 12187789
    Abstract: The present disclosure relates to compositions for treating interleukin 5 (IL-5) mediated diseases, and related methods.
    Type: Grant
    Filed: April 30, 2024
    Date of Patent: January 7, 2025
    Assignee: GlaxoSmithKline Intellectual Property (No.2) Limited
    Inventors: Myrna A. Monck, Narendra B. Bam, Jennifer Dally, Michelle Spatara
  • BIOPHARMACEUTICAL COMPOSITIONS
    Publication number: 20240294629
    Abstract: The present disclosure relates to compositions for treating interleukin 5 (IL-5) mediated diseases, and related methods.
    Type: Application
    Filed: April 30, 2024
    Publication date: September 5, 2024
    Inventors: Myrna A. MONCK, Narendra B. BAM, Jennifer DALLY, Michelle SPATARA
  • BIOPHARMACEUTICAL COMPOSITIONS
    Publication number: 20240294630
    Abstract: The present disclosure relates to compositions for treating interleukin 5 (IL-5) mediated diseases, and related methods.
    Type: Application
    Filed: April 30, 2024
    Publication date: September 5, 2024
    Inventors: Myrna A. MONCK, Narendra B. BAM, Jennifer DALLY, Michelle SPATARA
  • BIOPHARMACEUTICAL COMPOSITIONS
    Publication number: 20240294628
    Abstract: The present disclosure relates to compositions for treating interleukin 5 (IL-5) mediated diseases, and related methods.
    Type: Application
    Filed: April 30, 2024
    Publication date: September 5, 2024
    Inventors: Myrna A. MONCK, Narendra B. BAM, Jennifer DALLY, Michelle SPATARA
  • INTERLEUKIN 5 BINDING PROTEIN DOSAGE REGIMEN
    Publication number: 20240043524
    Abstract: The present disclosure relates to pharmaceutical compositions comprising from about 100 mg to about 300 mg of an antigen binding protein which binds to IL-5. Compositions and antigen binding proteins of the invention are useful in the treatment of IL-5 mediated diseases, such as asthma, and can be administered about once every 6 months.
    Type: Application
    Filed: December 20, 2021
    Publication date: February 8, 2024
    Inventors: Daren J AUSTIN, Nicholas P BIRD, Myrna A MONCK, Isabelle J POULIQUEN, Melissa A SHUMAN
  • BIOPHARMACEUTICAL COMPOSITIONS
    Publication number: 20220380452
    Abstract: The present disclosure relates to compositions for treating interleukin 5 (IL-5) mediated diseases, and related methods.
    Type: Application
    Filed: August 5, 2022
    Publication date: December 1, 2022
    Inventors: Myrna A. MONCK, Narendra B. Bam, Jennifer Dally, Michelle Spatara
  • Biopharmaceutical compositions
    Patent number: 11459384
    Abstract: The present disclosure relates to compositions, for treating interleukin 5 (IL-5) mediated diseases, and related methods.
    Type: Grant
    Filed: March 2, 2022
    Date of Patent: October 4, 2022
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED
    Inventors: Myrna A. Monck, Narendra B. Bam, Jennifer Dally, Michelle Spatara
  • BIOPHARMACEUTICAL COMPOSITIONS
    Publication number: 20220185878
    Abstract: The present disclosure relates to compositions, for treating interleukin 5 (IL-5) mediated diseases, and related methods.
    Type: Application
    Filed: March 2, 2022
    Publication date: June 16, 2022
    Inventors: Myrna A. MONCK, Narendra B. BAM, Jennifer DALLY, Michelle SPATARA
  • Biopharmaceutical compositions
    Patent number: 11299541
    Abstract: The present disclosure relates to compositions, for treating interleukin 5 (IL-5) mediated diseases, and related methods.
    Type: Grant
    Filed: July 12, 2021
    Date of Patent: April 12, 2022
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
    Inventors: Myrna A. Monck, Narendra B. Bam, Jennifer Dally, Michelle Spatara
  • Biopharmaceutical compositions
    Patent number: 11286298
    Abstract: The present disclosure relates to compositions, for treating interleukin 5 (IL-5) mediated diseases, and related methods.
    Type: Grant
    Filed: July 12, 2021
    Date of Patent: March 29, 2022
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED
    Inventors: Myrna A. Monck, Narendra B. Bam, Jennifer Dally, Michelle Spatara
  • Biopharmaceutical compositions
    Patent number: 11274148
    Abstract: The present disclosure relates to compositions, for treating interleukin 5 (IL-5) mediated diseases, and related methods.
    Type: Grant
    Filed: July 12, 2021
    Date of Patent: March 15, 2022
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
    Inventors: Myrna A. Monck, Narendra B. Bam, Jennifer Dally, Michelle Spatara
  • BIOPHARMACEUTICAL COMPOSITIONS
    Publication number: 20210340247
    Abstract: The present disclosure relates to compositions, for treating interleukin 5 (IL-5) mediated diseases, and related methods.
    Type: Application
    Filed: July 12, 2021
    Publication date: November 4, 2021
    Inventors: Myrna A. MONCK, Narendra B. BAM, Jennifer DALLY, Michelle SPATARA
  • BIOPHARMACEUTICAL COMPOSITIONS
    Publication number: 20210340246
    Abstract: The present disclosure relates to compositions, for treating interleukin 5 (IL-5) mediated diseases, and related methods.
    Type: Application
    Filed: July 12, 2021
    Publication date: November 4, 2021
    Inventors: Myrna A. MONCK, Narendra B. BAM, Jennifer DALLY, Michelle SPATARA
  • BIOPHARMACEUTICAL COMPOSITIONS
    Publication number: 20210332125
    Abstract: The present disclosure relates to compositions, for treating interleukin 5 (IL-5) mediated diseases, and related methods.
    Type: Application
    Filed: July 12, 2021
    Publication date: October 28, 2021
    Inventors: Myrna A. Monck, Narendra B. Bam, Jennifer Dally, Michelle Spatara
  • Biopharmaceutical compositions comprising interleukin-5 antibody
    Patent number: 10870695
    Abstract: The present disclosure relates to compositions, for treating interleukin 5 (IL-5) mediated diseases, and related methods.
    Type: Grant
    Filed: August 22, 2016
    Date of Patent: December 22, 2020
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED
    Inventors: Myrna A. Monck, Narendra B. Bam, Jennifer Dally, Michelle Spatara
  • BIOPHARMACEUTICAL COMPOSITIONS
    Publication number: 20200199219
    Abstract: The present disclosure relates to compositions, for treating interleukin 5 (IL-5) mediated diseases, and related methods.
    Type: Application
    Filed: March 2, 2020
    Publication date: June 25, 2020
    Inventors: Myrna A. MONCK, Narendra B. BAM, Jennifer DALLY, Michelle SPATARA
  • BIOPHARMACEUTICAL COMPOSITIONS
    Publication number: 20180251539
    Abstract: The present disclosure relates to compositions, for treating interleukin 5 (IL-5) mediated diseases, and related methods.
    Type: Application
    Filed: August 22, 2016
    Publication date: September 6, 2018
    Inventors: Myrna A. MONCK, Narendra B. BAM, Jennifer DALLY, Michelle SPATARA